Table 1.
Agents approved or in clinical development that target Siglecs as tumor-associated markers.
| Siglec/Sialic acid target | Drug name(s) | Status | Description |
|---|---|---|---|
| Siglec-2 (CD22) | |||
| UCART22 (Cellectis) | Phase I | Allogeneic anti-CD22 CAR T | |
| JCAR-018 (BMS) | Phase I | Anti-CD22 CAR T | |
| Senl H19×22P (AvalonGloboCare) | Phase I | Anti-CD22/CD19 CAR T | |
| MendCART (Hrain Biotechnology) | Phase I | Anti-CD22 CAR-T; NCT02721407 | |
| YT-19/22 (China Immunotech) | Phase I | Anti-CD19/anti-CD22 synthetic T-cell antigen receptor (STAR-T) | |
| AUTO1/22 (Autolus Therapeutics) | Phase I | Anti-CD19/anti-CD22 CAR T | |
| CTA-101 (Nanjing Bioheng Biotech) | Phase I | Anti-CD19/anti-CD22 CAR T | |
| LB-1909 (Nanjing Legend Biotech) | Phase I | Anti-CD19/anti-CD20/anti-CD22 CAR T | |
| GC-022 (Gracell Biotechnology) | Phase I | Anti-CD19/anti-CD22 CAR T; NCT04303247 | |
| TRPH-222 | Phase I (anticipated phase II to start in 2022) | Anti-CD22 ADC | |
| JNJ-75348780 (J&J) | Phase I | Anti-CD3/CD22 BiTE | |
| Inotuzumab ozogamicin (Besponsa, Pfizer) | Approved for use in acute lymphoblastic leukemia (ALL) | Anti-CD22 ADC | |
| Moxetumomab pasudotox (Lumoxiti, AstraZeneca) | Approved for use in hairy cell leukemia (HCL) | Anti-CD22 ADC | |
| Siglec-3 (CD33) a | |||
| Gemtuzumab ozogamicin (Mylotarg, Pfizer) | Approved for use in acute myeloid leukemia (AML) | ADC | |
| VOR33 (Vor BioPharma) | Phase I | Anti-CD33 CAR T being assessed in AML | |
| PRGN-3006 (Precigen) | Phase I | Autologous CAR T targeting CD33 in phase I for myeloid disorders | |
| ICG-136 (iCell Gene Therapeutics) | Phase I | Anti-CD33 CAR T being assessed in AML | |
| Eluvixtamab (AMG 330; Amgen) | Phase I | Anti-CD33/CD3 bispecific | |
| GEM333 (GEMoaB) | Phase I | Anti-CD33/CD3 bispecific | |
| JNJ-67571244 (J&J) | Phase I | Anti-CD33/CD3 bispecific | |
| CD33 NKE (BMS) | Phase I | NK-cell engager | |
aMany preclinical studies are ongoing. This table lists only clinical studies that appear to be active.